Seres Therapeutics, Inc.

Seres Therapeutics (MCRB) shows zero cyber incidents and zero red-flag 8-Ks in our 90-day monitoring window, indicating no acute governance or operational crises in recent months. However, low signal in this short window does not mean low risk; the company operates in the volatile biotech sector where financing history, equity dilution patterns, and liquidity pressures often drive material downside. The full $49 Report pulls 12 months of filing history, calculates a dilution risk score, maps all financing events with 8-K context, and surfaces AI-detected risk signals that short-window snapshots miss.